The Prognostic Role of Red Blood Cell Distribution (RDW) in Severe COVID-19 Patients

NCT07244731 | Completed

• 2 other identifiers: HTCGNSTEZİ10-808-24
• Study Type: observational
• Target: 146
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study was to evaluate the prognostic significance of erythrocyte distribution width (RDW) in severe and critically ill COVID-19 patients followed in the intensive care unit (ICU). RDW is a parameter that measures the heterogeneity in red blood cell size and is associated with the pathophysiological processes of COVID-19, such as systemic inflammation, oxidative stress, and erythropoiesis disorders. This study investigated the relationship between RDW and the need for intubation and mortality, and its utility as a prognostic marker in COVID-19 patients.

Conditions

COVID - 19; Prognosis; ICU

Keywords

COVID-19; Red Cell Distribution Width (RDW); Mortality; Intubation; Prognostic marker

Outcome Measures

Primary Outcomes (1)

• discharge / death

  discharge from the intensive care unit / death during intensive care follow-up

  From admission to the intensive care unit until ICU discharge or death, assessed up to 30 days.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Ministry of Health of the Republic of Turkey Ankara University Ibn-i-Sina Hospital Anaesthesiology and Resuscitation Department Patients admitted to the COVID-19 intensive care unit

You may qualify if:

• Patients aged 18 years and older
• Severe and critically ill COVID-19 patients (PCR test positivity of COVID)
• Patients who have been monitored in the intensive care unit for at least 3 days
• Patients without haematological malignancies

You may not qualify if:

• Patients under 18 years of age
• Those with haematological malignancies (as this may affect RDW levels)
• Patients who died within 3 days of admission to intensive care

Sponsors & Collaborators

• Ankara University: lead

Study Sites (1)

Ankara University

Ankara, Ankara, 06340, Turkey (Türkiye)

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Mustafa Necmettin Ünal

  Ankara University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Specialist in Anesthesiology

Study Record Dates

• First Submitted: October 1, 2025
• First Posted: November 24, 2025
• Study Start: September 1, 2024
• Primary Completion: June 1, 2025
• Study Completion: June 1, 2025
• Last Updated: November 24, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)